Saluda Medical Announces Publication of 24-Month Spinal Cord Stimulation Results with the Evoke® System

Link to Full Article Results show ~90% overall back and leg responder rate, ~68% high responder rate, and zero explants due to loss of efficacy ~83% of patients reduced or eliminated opioid use Need for patient re-programming visits nearly eliminated after 12 months Represents the first peer reviewed SCS study to show responder and high […]

Saluda Medical Announces Executive Leadership Changes

Link to Full Article Founder, CEO John Parker Taking on New Role as Chief Scientific Officer, Remaining on Board Artarmon, Australia – February 12, 2021 – Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of novel closed-loop spinal cord stimulation (SCS) for the treatment of chronic pain, today announced the appointment of Jim Schuermann […]

Saluda Medical Announces Highlights from 2021 North American Neuromodulation Society (NANS) Meeting

Link to Full Article Artarmon, Australia – January 20, 2021 – Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of closed-loop spinal cord stimulation for the treatment of chronic pain, announced scientific highlights from the 2021 North American Neuromodulation Society (NANS 2021) Virtual Meeting, including real-world European commercial results and sub-analyses of 24-month […]

NICE Publishes Briefing on Saluda’s Evoke Closed-Loop Spinal Cord Stimulation (SCS) System

Link to Full Article Artarmon, Australia – December 22, 2020 – Saluda Medical Pty Limited (“Saluda Medical”) announced today that the UK’s National Institute for Health and Care Excellence (NICE) issued a Medtech Innovation Briefing (MIB) titled “Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain.” The MIB states Evoke would be used as a […]

Saluda Medical Appoints Jim Schuermann as President and Robert Gaffney as Chief Operating Officer

Link to Full Article Strengthens corporate leadership as company moves toward global commercialization Artarmon, Australia – June 9, 2020 – Saluda Medical Pty Limited (“Saluda Medical”), a global neuromodulation company leading the development and commercialization of data-driven, personalized therapies for patients with debilitating neurological disorders, today announced the key leadership appointments of Jim Schuermann as President and Robert Gaffney as Chief Operating […]

Saluda Medical Highlights Multiple Presentations Featuring Evoke® ECAP-Controlled, Closed-Loop SCS System at NANS Annual Meeting

Link to Full Article ARTARMON, NSW, Australia, January 21, 2020 – Saluda Medical Pty Limited (“Saluda Medical”) today announced that data from multiple studies evaluating the company’s Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System for the treatment of chronic pain will be featured in multiple presentations – including eight oral presentations and award of Best Clinical Abstract – during […]

Saluda Medical Results of U.S. Evoke Pivotal Study through 12 Months Published in The Lancet Neurology

Link to Full Article ARTARMON , Australia, Dec. 20, 2019 /PRNewswire/ — Saluda Medical Pty Limited (“Saluda Medical”) today announced The Lancet Neurology journal published results from the U.S. Pivotal Study demonstrating its Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System provided long-term, statistically superior, and clinically meaningful pain relief for patients with chronic intractable back and leg pain out […]

Regulatory approval next hurdle for Saluda Medical

Link to Full Article Regulatory approval is the next major hurdle facing Saluda Medical, the biotech company which is led by Cochlear’s former chief technology officer and was responsible for the biggest domestic life sciences capital raising of the last fiscal year. Saluda Medical said in June it had raised $US75 million ($106 million) from […]

Saluda Medical Raises $75 Million Equity Financing from Boston Scientific and Redmile Group

Artarmon, NSW, Australia – June 28, 2019 – Saluda Medical Pty Limited (“Saluda Medical”) today announced that it has secured $75 million in equity financing from Boston Scientific Corporation (NYSE: BSX) and Redmile Group LLC to fund the final stages of development through commercialization of its Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System for […]

Saluda Medical Secures Debt Financing From Medtronic

Proceeds to fund continued development of Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System Evoke Trial Validates Level I Evidence Achieved Through First Double-Blind Randomized U.S. Pivotal Study in SCS Proceeds to fund continued development of Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System Evoke Trial Validates Level I Evidence Achieved Through First Double-Blind Randomized U.S. […]